Bio Connections Australia
Translation | Commercialising Great Science | Partnering for Growth
27 July 2026 | Crown Promenade Melbourne
Bio Connections Australia is the annual flagship event for the biotech industry, offering a premier platform for networking, meaningful discussions, and groundbreaking thought leadership.
The conference centers on accelerating the translation of medical research into real-world applications, with a strong emphasis on commercialisation, drug discovery and development, early-phase clinical trials, and bringing Australia’s cutting-edge science to market.
Each year, the event brings together a diverse mix of senior decision-makers from across the sector, including pharmaceutical leaders, investors, local and international biotech companies, researchers, CROs, Phase 1 units, universities, government agencies, and regulators.
Key Topics:
- Investment Trends in 2026
- Retail Investor Sentiment in Life Sciences
- Exploring New Therapeutic Modalities
- Australia as a Global Clinical Trials Hub
- Why mRNA Matters for Australia
- Australia’s Biotech Manufacturing Future
- Addressing the underutilization of CROs & CDMOs in Australia
- University Collaborations and IP Ownership
- The 2026 tax reforms
- How can Australia position itself as a global leader in biotech innovation
Who attends
Pharmaceutical leaders, investors, local and international biotech companies, researchers, CROs, CDMO’s, Phase 1 units, universities, government agencies, and regulators.

2026 SPEAKERS
BREAKFAST BRIEFING
From Barriers to Breakthroughs: Unlocking Innovation in Australia
The health biotechnology sector in Australia faces significant innovation barriers, despite being a global leader in medical research. While Australia is globally ranked in the top 10 for life sciences and generates roughly 2.7% of the world’s scientific output, it faces significant barriers to scaling these innovations domestically. The core challenges revolve around navigating the “valley of death” between research discovery and commercialization, primarily driven by a lack of capital, skills shortages, and complex regulatory environments.
- What initiatives or programs could be introduced to better support early-stage biotech companies in overcoming funding and resource challenges?
- Skill shortages in the biotech industry, particularly mid and high-tier scientific talent.
- How can industry stakeholders collaborate to create a more supportive environment for innovation?
NETWORKING DINNER
Monday 28th July | 7pm – 10pm
Ludlow Bar & Dining – located on the banks of the Yarra River
6 Riverside Quay, Southbank, Melbourne
Join fellow delegates and speakers for an informal, relaxed networking dinner. Enjoying canapes on arrival followed by sit down for 2 courses and drinks throughout the evening.
Numbers to the dinner are limited, book early to avoid disappointment.
2025 EVENT PHOTOS
INSIGHTS
What is the pathway to success in biotech?
A researcher who is making headway with a novel dementia treatment, targeting small molecules, is giving his view on what success looks like for the Australian biotech sector...
What Imugene CEO Leslie Chong has learned in her bid to create the world’s best immunotherapy
When Leslie Chong took over Imugene as Chief Executive in 2015, she was excited to progress the development of what could be the world’s first cancer vaccines...
Accelerating the pathways between mouse and human in biomedical research
Australia’s medical research sector is thriving, with this year seeing record levels of government investment ($6.8 billion) – and sizeable contributions from the private sector...
How supply chain enhancements can boost medication compliance rates
The pharmaceutical industry’s response to the COVID-19 pandemic has raised the bar for therapeutic development, with vaccine generation and approval performed in record timeframes...
How AUM Biosciences is improving drug availability and affordability worldwide
An award winning biotech startup, AUM Biosciences, is addressing the low returns on R&D investment that currently exist in oncology drug development, with a view to improving drug availability and affordability, worldwide...
Clinical trial partnerships with Australia | a US pharmaceutical firm case study
Over the years, Australia has established itself as an attractive early phase clinical trial destination, within a competitive global marketplace...
Is Australia your next best destination for clinical trials?
Australia is home to some of the world’s leading scientists, physicians and healthcare providers. With world-class research capabilities and a thriving biotech sector, the number of clinical trials...
Clinical Trials Report Highlights Australia’s Competitive Advantages… And Weaknesses
A 2017 report found that Australia’s clinical trials sector is large. As international competition for clinical trials intensifies, Australian medtech trade group, MTAA, has pledged to work...
Australia’s Capability in Clinical Trials
Earlier this year, Austrade released the new Clinical Trials industry capability report which highlights why Australia is a leading destination for clinical research of new...
Status Quo or No? 2017 Completed Clinical Trials
A completed clinical trial landscape provides a more granular view of how companies are progressing their pipelines and the disease strategies they are pursuing, compared to...
WHEN & WHERE
27 Jul 2026
Crown Promenade Melbourne
8 Whiteman St,
Southbank VIC 3006














